Tetracyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos Patents (Class 514/284)
  • Patent number: 10440975
    Abstract: The present disclosure relates to a feed additive composition for reducing methane production generated in the ruminant stomach of ruminant animals. Specifically, the present disclosure relates to a feed additive composition for reducing methane production comprising at least one selected from the group consisting of alliin and berberine, more specifically to a feed additive composition for reducing methane production comprising at least one selected from the group consisting of diallyl disulfide (DADS), nitrate, and eucalyptus oil. The feed additive composition according to the present disclosure may be added to the feed without additional treatment, thereby reducing the amount of methane production in the ruminant stomach without negative effects on livestock productivity. Thus, the feed additive composition can be effectively used in the ruminant animal industry.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: October 15, 2019
    Assignee: CJ CHEILJEDANG CORPORATION
    Inventors: Min Ah Park, Seung Heon Lee, Sung Hun Kim, In Bae Kim, Si Yong Yang, Seok Woo Chee
  • Patent number: 10413517
    Abstract: Methods and compositions which include or include the administration of a hydrophobic drug, prodrug thereof, salt thereof, isoform thereof, or a combination thereof; cyclodextrin, prodrug thereof, salt thereof, or a combination thereof; polyethylene glycol, propylene glycol, or combination thereof; and optionally, a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: June 11, 2015
    Date of Patent: September 17, 2019
    Assignee: UNIVERSITY OF NOTRE DAME DU LAC
    Inventors: Kasturi Haldar, Md. Suhail Alam
  • Patent number: 10046007
    Abstract: The invention generally relates to methods of treating short telomere disorders using known compounds and pharmaceutical compositions comprising same. More specifically, the disclosed methods comprise, in one aspect, the step of administering to the subject an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, thereby treating the subject for the short telomere disorder. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: August 14, 2018
    Assignee: Prescient Pharma, LLC
    Inventors: Pavel Idelevich, Yanming Wang
  • Patent number: 9808470
    Abstract: The invention relates to the prophylactic and therapeutic applications of certain estrogenic components, such as estetrol in neurological disorders, such as diffuse white matter injury.
    Type: Grant
    Filed: December 9, 2015
    Date of Patent: November 7, 2017
    Assignee: UNIVERSITE DE LIEGE
    Inventors: Jean-Michel Foidart, Ekaterine Tskitishvili, Renaud Viellevoye
  • Patent number: 9573895
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula (I) are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula (I), or a pharmaceutically acceptable salt thereof, and its therapeutic use.
    Type: Grant
    Filed: August 30, 2013
    Date of Patent: February 21, 2017
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Xiao-Yi Xiao, Roger B. Clark, Diana Katharine Hunt, Cuixiang Sun, Magnus P. Ronn, Wu-Yan Zhang, Minsheng He
  • Patent number: 9540375
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Grant
    Filed: May 17, 2016
    Date of Patent: January 10, 2017
    Assignees: University of Kansas, The Scripps Research Institute
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin J. Frankowski
  • Patent number: 9399660
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: July 26, 2016
    Assignees: Purdue Research Foundation, NATIONAL INSTITUTES OF HEALTH (NIH)
    Inventors: Mark S. Cushman, Yves George Pommier, Peng-Cheng Lu, Christophe Marchand, Keli Agama
  • Patent number: 9388211
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: July 12, 2016
    Assignees: Purdue Research Foundation, NATIONAL INSTITUTES OF HEALTH (NIH)
    Inventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves George Pommier, Smitha Antony, Keli K. Agama, Daniel E. Beck
  • Patent number: 9345703
    Abstract: The present invention is a selective kappa opioid receptor effector, or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, anxiety and/or depression, schizophrenia, mania or post-traumatic stress disorder.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: May 24, 2016
    Assignees: University of Kansas, The Scripps Research Institute
    Inventors: Jeffrey Aube, Laura Bohn, Thomas Edward Prisinzano, Frank John Schoenen, Kevin John Frankowski
  • Publication number: 20150148370
    Abstract: The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein RA, RD, W, X and Y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.
    Type: Application
    Filed: May 24, 2012
    Publication date: May 28, 2015
    Applicant: PURDUE RESEARCH FOUNDATION
    Inventors: Mark S. Cushman, Yves George Pommier
  • Publication number: 20150133445
    Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
    Type: Application
    Filed: November 10, 2014
    Publication date: May 14, 2015
    Inventors: Mark S. CUSHMAN, Trung X. Nguyen, Martin M. Conda-Sheridan, Yves George Pommier
  • Publication number: 20150125389
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R4, R5, X1, X2, X3 and X4 are as defined herein, and wherein the compound comprises at least one F, Cl, Br, I or 123I moiety, are provided. Uses of such compounds for imaging diagnostics in cancer and therapeutics methods for treatment of subjects in need thereof, including prostate cancer as well as methods and intermediates for preparing such compounds are also provided.
    Type: Application
    Filed: September 9, 2014
    Publication date: May 7, 2015
    Applicants: THE UNIVERSITY OF BRITISH COLUMBIA, BRITISH COLUMBIA CANCER AGENCY BRANCH
    Inventors: Raymond John Andersen, Carmen Adriana Banuelos, Javier GARCIA FERNANDEZ, Yusuke IMAMURA, Jian KUNZHONG, Nasrin R. MAWJI, Marianne Dorothy Sadar, Jun Wang, Amy (Hsing Chen) Tien
  • Publication number: 20150119324
    Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.
    Type: Application
    Filed: January 5, 2015
    Publication date: April 30, 2015
    Inventor: Benjamin S. Bleier
  • Publication number: 20150099772
    Abstract: The present invention provides substituted berbines, processes for the synthesis of substituted berbine compounds, as well as intermediates used in the synthesis of substituted berbine compounds. Also provided are methods for using the substituted berbines to inhibit cancer cell growth.
    Type: Application
    Filed: October 2, 2014
    Publication date: April 9, 2015
    Inventor: Christopher W. Grote
  • Patent number: 8999955
    Abstract: The invention relates to kinase inhibitors of the formula (I) in which —R1 to R4?H; ether or polyether, amino; NO2; NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; —R5=—OH; halogen; —OR with R such as defined above; OH-carbamate; OH-carbonate; NH2, NH-carbamate; NH—CO—R, with R such as defined above; N3 and derivatives thereof of the 1,2,3-triazole type; N(R9,R10); —R5??H or a C1-C12 alkyl, —R6?H; R; (R or R?)3—Si, with R such as defined above; optionally substituted aryl, heteroaryl; halogen (iodine); alkynyl; —R7 and R8?H, C1-C12 alkyl; —R9 and R10?H, R (or R?) such as defined above. These compounds can be used as kinase inhibitors in particular for treating cancer.
    Type: Grant
    Filed: January 19, 2009
    Date of Patent: April 7, 2015
    Assignee: Centre National de la Recherche Scientifique
    Inventors: Philippe Olivier Belmont, Laurent Meijer, Philip Cohen, Amaury Patin, Johann Bosson, Peter Gregory Goekjian
  • Publication number: 20150087633
    Abstract: Disclosed embodiments concern polycyclic alkaloid compounds and methods for their use and synthesis. Particular embodiments concern polycyclic alkaloids having a fused, six-membered ring, while other embodiments concern polycyclic alkaloids having a fused, five-membered ring. Methods for making the polycyclic alkaloids are disclosed, as well as methods for their use as prophylactics or treatments for certain diseases. Also disclosed are pharmaceutical compositions comprising the polycyclic alkaloids and their use.
    Type: Application
    Filed: December 1, 2014
    Publication date: March 26, 2015
    Applicant: Rigel Pharmaceuticals, Inc.
    Inventors: Dane Goff, Donald D. Payan, Sylvia Braselmann
  • Publication number: 20150064168
    Abstract: Cadherin-11 inhibitors and methods for the prevention and treatment of cadherin-11 related diseases are described herein. Cadherin-11 related diseases include cancer and rheumatoid arthritis.
    Type: Application
    Filed: July 3, 2014
    Publication date: March 5, 2015
    Inventors: Stephen W. Byers, Sivanesan Dakshanamurthy, Jaime M. Guidry Auvil, Milton L. Brown
  • Publication number: 20150044284
    Abstract: The present invention describes new and improved dosage forms containing a steroid 5-alpha-reductase inhibitor, in combination with an alpha blocker, for the treatment or prophylaxis of an androgen mediated disease or condition, preferably for the treatment of benign prostatic hyperplasia (HPB).
    Type: Application
    Filed: August 11, 2014
    Publication date: February 12, 2015
    Inventors: Giancarlos SANTUS, Giuseppe Soldati, Luca Donadoni
  • Publication number: 20150025067
    Abstract: Inhibitors of p67phox protein are provided herein, as well as pharmaceutical compositions and methods relating thereto.
    Type: Application
    Filed: February 13, 2013
    Publication date: January 22, 2015
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Yi Zheng, Prakash Jagtap, Emily E. Bosco, Jaroslaw Meller, Marie-Dominique Filippi
  • Publication number: 20150025043
    Abstract: Provided are stable liquid and solid formulations of oxidized and reduced mitochondria-targeted antioxidants, and methods of their preparation and use.
    Type: Application
    Filed: June 4, 2012
    Publication date: January 22, 2015
    Applicant: Mitotech SA
    Inventors: Maxim V. Skulachev, Vladimir P. Skulachev, Andrey A. Zamyatnin, Vadim N. Tashlitsky, Roman A. Zinovkin, Maxim V. Egorov, Lawrence T. Friedhoff, Olga Y. Pletushkina, Alexander A. Andreev-Andrievsky, Tatiana V. Zinevich
  • Publication number: 20150024045
    Abstract: Embodiments of liquid-filled hard gel capsule pharmaceutical formulations comprise a non-emulsified mixture, wherein the non-emulsified mixture comprises about 0.1 to about 5% by weight of at least one active pharmaceutical ingredient, about 50 to about 95% by weight long chain triglycerides, and about 5 to about 25% by weight medium chain mono/diglycerides, wherein the long chain triglycerides and medium chain mono/diglycerides are present at a ratio by weight of from about 10:1 to about 5:1.
    Type: Application
    Filed: October 9, 2014
    Publication date: January 22, 2015
    Applicant: MYLAN INC.
    Inventors: Sarat C. Chattaraj, Glenn Allen Redelman
  • Publication number: 20150011516
    Abstract: Pharmaceutical compositions that bind to a predicted FK506 Binding Protein 52 (FKBP52) interaction surface on the androgen receptor hormone binding domain, otherwise known as FKBP52 Targeting Agents (FTAs) are provided. These compositions of the present invention are found to specifically recognize the FKBP52 regulatory surface on the androgen receptor and inhibit FKBP52 from functionally interacting with the androgen receptor. Compositions comprising the pharmaceutical composition, as well as methods of use, treatment and screening are also provided.
    Type: Application
    Filed: July 21, 2014
    Publication date: January 8, 2015
    Inventors: Leonard M. Neckers, Marc B. Cox, Jane B. Neckers, Yeong Sang Kim, Aki Iwai, Yangmin Ning, Johanny Tonos de Leon, Heather A. Balsiger, Robert Fletterick
  • Patent number: 8927565
    Abstract: Compositions including polymeric dialdehydes and compounds of where R1, R2, R7, R8, R9, and R10 may be the same or different and are selected from H, CH3, OH, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl; R3, R4, R5, R6 may be the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl, or R5 and R6 are the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl and R3 and R4 together are ?O, or R4 and R6 are the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl and R3 and R5 together form a double bond or are ?O, or R3 and R4, are the same or different and are selected from H, CH3, OCH3, C2H5, OC2H5OCH2Ph, OCH2PhNO2, F or Cl and R5 and R6 together are ?O; R11 and R12 together form ?CH2, or R11 and R12 may be the same or different and are independently selected from the group consisting of H, CH3, CH2CH3 and CH2CH2CH3; and X is selected from the group consisting of Cl, Br, SO4, I and R13COO,
    Type: Grant
    Filed: August 26, 2004
    Date of Patent: January 6, 2015
    Assignee: Australian Biomedical Company Pty. Ltd.
    Inventors: Betty Jin, Wen-Yang Wu
  • Publication number: 20140377384
    Abstract: The invention encompasses a formulation for hair loss prevention comprising a mixture of water and at least one nonpolar aprotic organic solvent and at least one hair loss preventive ingredient known to inhibit the hormonal mechanism underlying androgenetic hair loss and methods of using the same.
    Type: Application
    Filed: September 14, 2014
    Publication date: December 25, 2014
    Inventor: Giuseppe Trigiante
  • Publication number: 20140377329
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Application
    Filed: September 5, 2014
    Publication date: December 25, 2014
    Inventors: Nathan John BRYSON, Anthony John GIOVINAZZO, Scott David BARNHART, Michael Clinton KOONS
  • Patent number: 8916161
    Abstract: The present invention provides a method of treating BPH using modified pore-forming proteins (MPPs). These MPPs are derived from naturally occurring cytotoxic proteins (nPPs) that kill cells by forming pores or channels in the cell membrane, resulting in cell death. The MPPs are generated by modification of the nPPs such that they are capable of being selectively activated at normal prostate cells. Such modification may include the addition of a prostate-specific protease cleavage site to the activation sequence, and/or the addition of a prostate-specific targeting domain to allow selective targeting of prostate cells. These MPPs are capable of selectively targeting and killing normal prostate cells in vivo. The MPPs may be used either alone or in combination with other therapies for the treatment of BPH.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: December 23, 2014
    Assignee: Sophiris Bio Inc.
    Inventor: James Thomas Buckley
  • Patent number: 8912213
    Abstract: The invention described herein pertains to the synthesis and use of certain N-substituted indenoisoquinoline compounds which inhibit the activity Tyrosyl-DNA Phosphodiesterase I (Tdp1) or Topoisomerase I (Top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel N-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel N-substituted indenoisoquinoline compounds.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: December 16, 2014
    Assignee: Purdue Research Foundation
    Inventors: Mark S. Cushman, Trung X. Nguyen, Martin M. Conda-Sheridan, Yves G. Pommier
  • Publication number: 20140336188
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Application
    Filed: July 24, 2014
    Publication date: November 13, 2014
    Applicants: PURDUE RESEARCH FOUNDATION, THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETSR
    Inventors: Mark S. CUSHMAN, Andrew E. MORRELL, Muthukaman NAGARAJAN, Yves G. POMMIER, Keli K. AGAMA, Smitha ANTONY
  • Publication number: 20140322148
    Abstract: Described herein are topical oil-based formulations that find use in the treatment of alopecia, i.e., hair loss, and in the promotion of hair growth.
    Type: Application
    Filed: November 20, 2012
    Publication date: October 30, 2014
    Inventor: Adrianna Janell JACKSON
  • Publication number: 20140323420
    Abstract: Described herein are compositions and methods for treating or preventing a sexually transmitted infection in a subject
    Type: Application
    Filed: November 8, 2012
    Publication date: October 30, 2014
    Inventors: Stephen Dewhurst, David Easterhoff, Brad Nilsson, John Dimaio, Alan Smrcka, Jerry Yang, Christina Capule
  • Patent number: 8871781
    Abstract: Methods of treating lymphatic malformations using a phosphodiesterase type 5 inhibitor are provided. Pharmaceutical compositions and kits comprising phosphodiesterase type 5 inhibitors are also provided.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: October 28, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Alfred T. Lane, David Berk, Anna L. Bruckner, Glenda Louise Swetman
  • Publication number: 20140315939
    Abstract: The invention provides a compound of formula I: or a salt or prodrug thereof, wherein Y, W, Z, Z1, Z2, Z3, Z4, and R1-R12 have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.
    Type: Application
    Filed: February 21, 2014
    Publication date: October 23, 2014
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Daniel S. Pilch, Ajit Parhi, Malvika Kaul
  • Publication number: 20140315808
    Abstract: A method of treating a disease or condition in which up-regulating GAGs is therapeutically beneficial is disclosed. The method comprises locally administering to a subject a therapeutically effective amount of an agent capable of down-regulating activity or expression of a component of the renin-angiotensin system.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 23, 2014
    Inventors: Talia WEINSTEIN, Uzi GAFTER, Zvi NEVO, Dror ROBINSON, Zoharia EVRON
  • Patent number: 8865143
    Abstract: A reversely thermo-reversible hydrogel composition comprising a water soluble block copolymer comprising at least two blocks of polyethylene oxide and at least one block of polypropylene oxide, and at least one associative gelling adjuvant having water solubility less than 0.5 g/100 ml, preferably less than 0.3 g/100 ml at 20° C., and being capable of forming water soluble inter-molecular complexes with the water soluble block copolymer in water. The hydrogel composition exhibits improved gelling efficiency, enhanced solubility and/or stability for water sparely soluble and insoluble pharmaceutical agents. The hydrogel compositions are useful in a variety of pharmaceutical and cosmetic products and applications, such as esophageal, otic, vaginal, rectal, ophthalmic, treatments of disorders and imperfections of the skin, and treating and/or preventing alopecia and restoring and/or promoting hair growth.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 21, 2014
    Assignee: Broda Technologies Co., Ltd.
    Inventors: Shao Xiang Lu, Jeffrey Lu, Letian Liu
  • Publication number: 20140309185
    Abstract: This document relates to inhibitors of G protein coupled receptor 6 kinase (GRK6) polypeptides as well as methods and materials for using such inhibitors to treat hematological malignancies, inflammation diseases, and autoimmune disorders.
    Type: Application
    Filed: October 26, 2012
    Publication date: October 16, 2014
    Inventors: Alexander Keith Stewart, Artem Plekhov, Robert Greenhouse
  • Publication number: 20140309247
    Abstract: Methods, processes, systems, and apparatuses are disclosed for detecting biomarkers associated with the inflammation response in the pilosebaceous unit of the human scalp using plucked human hair and an enzyme activity assay which may for example be colorimetric or fluorometric.
    Type: Application
    Filed: April 15, 2013
    Publication date: October 16, 2014
    Inventors: Andy Ofer Goren, John McCoy
  • Patent number: 8846074
    Abstract: The invention features sublingual film formulations of dopamine agonists and methods of treating Parkinson's disease, tremors, restless leg syndrome, sexual dysfunction, and depressive disorders therewith.
    Type: Grant
    Filed: April 8, 2013
    Date of Patent: September 30, 2014
    Assignees: Cynapsus Therapeutics, Inc., ARx, LLC
    Inventors: Nathan John Bryson, Anthony John Giovinazzo, Scott David Barnhart, Michael Clinton Koons
  • Publication number: 20140287918
    Abstract: Use of a Peumus Boldus extract obtained by in vitro culture, with antibotricide, allelochemical and antioxidant capacity.
    Type: Application
    Filed: October 19, 2012
    Publication date: September 25, 2014
    Inventor: Gustavo Zuniga
  • Publication number: 20140271845
    Abstract: Pharmaceutical compositions in unit dose form comprising a hollow substrate and one or more coatings on the hollow substrate, wherein at least one coating comprises at least one active pharmaceutical ingredient, and methods of making the same are provided.
    Type: Application
    Filed: March 18, 2014
    Publication date: September 18, 2014
    Applicant: Cerovene, Inc.
    Inventors: Manish S. SHAH, Ray J. DiFalco
  • Publication number: 20140256627
    Abstract: Provided are methods of delivering at least one pharmaceutical agent to the central nervous system (CNS) of a subject, methods of treating a neurological disorder or pain in a subject that include administering at least one pharmaceutical agent onto a SEM graft in the skull base of the subject. Also provided are methods of treating a neurological disorder or pain in a subject that include forming a SEM graft in the skull base of the subject and administering at least one pharmaceutical agent onto the SEM graft in the skull base of the subject. Also provided are methods of forming a SEM graft in the skull base of a subject, compositions for administration onto a SEM graft in the skull base or into an endonasal reservoir or endonasal reservoir device in a subject, and devices for administering such compositions onto a SEM graft in the skull base of a subject.
    Type: Application
    Filed: February 4, 2014
    Publication date: September 11, 2014
    Applicant: Massachusetts Eye and Ear Infirmary
    Inventor: Benjamin S. Bleier
  • Patent number: 8829022
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: October 11, 2011
    Date of Patent: September 9, 2014
    Assignees: Purdue Research Foundation, The United States of America as represented by the Department of Health and Human Services
    Inventors: Mark S. Cushman, Andrew E. Morrell, Muthukaman Nagarajan, Yves G. Pommier, Keli K. Agama, Smitha Antony
  • Patent number: 8829023
    Abstract: The invention relates to a process for obtaining compounds derived from tetrahydro-?-carboline, specifically tadalafil and intermediate products from the synthesis, comprising the reaction between piperonal and an alkyl ester of D-tryptophan as a salt, and in the absence of any other component, followed by haloacetylation and a final cyclization with methylamine.
    Type: Grant
    Filed: February 10, 2012
    Date of Patent: September 9, 2014
    Assignee: Interquim, S.A.
    Inventors: Xavier Berzosa Rodríguez, Francisco Marquillas Olondriz
  • Patent number: 8828988
    Abstract: The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.
    Type: Grant
    Filed: December 31, 2012
    Date of Patent: September 9, 2014
    Assignee: Tetraphase Pharmaceuticals, Inc.
    Inventors: Roger B. Clark, Minsheng He, Louis Plamondon, Xiao-Yi Xiao, Magnus P. Rönn
  • Patent number: 8822442
    Abstract: The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions.
    Type: Grant
    Filed: October 28, 2005
    Date of Patent: September 2, 2014
    Assignee: Ipsen Pharma S.A.S.
    Inventors: Zheng Xin Dong, Michael Dewitt Culler, Yeelena Shen
  • Publication number: 20140228355
    Abstract: The present invention provides a method of inhibiting, suppressing or preventing levodopa-induced dyskinesia in a patient suffering from Parkinson's Disease, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention. The present invention further provides a method of inhibiting, suppressing or preventing Parkinson's Disease in a patient, comprising the step of administering to the patient a pharmaceutical composition comprising at least one compound of the invention.
    Type: Application
    Filed: February 11, 2013
    Publication date: August 14, 2014
    Applicants: University of Medicine and Dentistry New Jersey Medical School, Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine
    Inventors: Philadelphia Health & Education Corporation d/b/a Drexel University College of Medicine, University of Medicine and Dentistry New Jersey Medical School
  • Publication number: 20140194450
    Abstract: The present invention is directed to compositions and methods for the treatment of post-chemotherapeutic hypotrichosis. More specifically, the present invention is directed to the use of compositions comprising bimatoprost for the treatment of post-chemotherapeutic hypotrichosis which may be applied before, during and after receiving chemotherapeutic treatment.
    Type: Application
    Filed: January 10, 2013
    Publication date: July 10, 2014
    Applicant: ALLERGAN, INC.
    Inventors: Gurpreet Ahluwalia, Frederick C. Beddingfield, Sydney G. Edwards, Scott M. Whitcup
  • Publication number: 20140194459
    Abstract: Methods and compositions for the treatment of alpha-adrenoceptor mediated conditions.
    Type: Application
    Filed: March 5, 2014
    Publication date: July 10, 2014
    Applicant: Vanda Pharmaceuticals, Inc.
    Inventors: Mihael H. Polymeropoulos, Paolo Baroldi, Curt D. Wolfgang
  • Patent number: 8772309
    Abstract: The present invention provides a kit comprising, in separate compartments of a container, the following components (a) and (b): (a) a combination of apomorphine or a pharmaceutically acceptable acid addition salt thereof and a pharmaceutically acceptable excipient or carrier; and (b) a solution which comprises a diluent and a pH modifying agent; the components being presented such that they can be combined at the point of use into a formulation which is adjusted to a pH ranging from mildly acidic to alkaline and which is suitable for buccal administration. The formulation is useful in treating Parkinson's disease and in promoting sexual function.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: July 8, 2014
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Anthony Clarke
  • Publication number: 20140179653
    Abstract: Orally disintegrating film dosage forms for delivering active pharmaceutical agents, methods of formulating the dosage forms to retard absorption through the oral mucosa, and methods of using the dosage forms for the treatment of various medical conditions are provided.
    Type: Application
    Filed: October 11, 2013
    Publication date: June 26, 2014
    Applicants: APR APPLIED PHARMA RESEARCH SA, LABTEC GESELLSCHAFT FUR TECHNOLOGISCHE FORSCHUNG UND ENTWICKLUNG MBH
    Inventors: Christian Leichs, Armin Breitenbach, Ingo Lehrke, Paolo Galfetti
  • Patent number: 8741917
    Abstract: The present invention provides compounds of formula I: formula (I) wherein X1-X4 and R1-R12 have any of the values defined in the specification, as well as salts and prodrugs thereof, which inhibit major molecular mechanisms associated with bacterial cell division and proliferation so as to be useful for the treatment and/or prevention of bacterial infections. The invention also provides compositions comprising these compounds as well as methods for using these compounds to inhibit bacterial cell division and proliferation and to treat bacterial infections.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: June 3, 2014
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Edmond J. LaVoie, Ajit Parhi, Daniel S. Pilch, Malvika Kaul